Immunic shareholders approve 7M share increase in equity plan, elect three Class II directors

IMMUNIC, INC.

Plan amendment increases authorized shares by 7,000,000 to 26,448,871; approved with 32,765,299 for, 10,731,124 against.
Dr. Jörg Neermann, Tamar Howson, and Barclay Phillips elected as Class II directors until 2028.
Baker Tilly US, LLP ratified as independent auditor for fiscal 2025 with 60,427,763 votes for.
Quorum of 61,229,143 shares (63.9% of outstanding) present at June 4, 2025 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.